Tregitopes are small peptidic regulatory T-cell epitopes derived from human immunoglobulins that activate regulatory T cells (Tregs). Tregitope therapy has broad-reaching implications, offering new treatments for autoimmune diseases (e.g. type 1 juvenile diabetes, multiple sclerosis, rheumatoid arthritis, and lupus), allergies, and transplantation rejection. In previous meetings, the members of the Tregitope Collaborators team have demonstrated the immune suppressive capacity of Tregitopes. Ongoing research in the laboratories of the collaborators seeks to define the mechanism by which Tregitopes regulate immune responses and thereby accelerate the translation of this novel therapy to the clinic. Continue reading →